Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
AssigneesTonix Pharmaceuticals Holding Corp, Tonix Pharma Limited
InventorsSeth Lederman, Siobhan J. Fogarty
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for detecting cell-mediated immunity to SARS-CoV-2 in a subject, methods for detecting a cell-mediated immune response against SARS-CoV-2 in a subject and methods for determining if a vaccine against SARS-CoV-2 elicits a cell-mediated immune response in a subject, comprising administering to the skin of the subject one or more peptides.
Claims27
A method for detecting SARS-CoV-2 cell-mediated immunity in a subject, the method comprising administering to the skin of the subject one or more peptides, at least one, at least five, at least ten, at least fifteen, at least twenty, at least twenty-five, at least thirty of the one or more peptides being selected from the group consisting of peptides being characterized by the amino acid sequences set forth in SEQ ID NO:
- 1-358 and inspecting the skin region in the area of the administration for an immune reaction, wherein the presence of an immune reaction is indicative of the subject having developed cell-mediated immunity to SARS-CoV-2.
A combination or pool of peptides comprising at least one or more of the peptides with the amino acid sequence of SEQ ID NO:
- 1-14, 16-48, 50-55, 57-64, 66-72, 74-77, 79-81, 83, 84, 86, 87, 89-94, 96, 99-101, 103, 105-111, 113-126, 128-133, 136-142, 144, 146-149, 151-155, 158-168, 170, 171, 173, 175, 176, 178, 179, 181, 190, 235-248, 250-255, 257-261, 266, 268, 265, 272, 274, 275, 277-283, 290-306, 308-322, 324, 325, 328, 328, 330-334, 337-340, and 342-358.
Dependencies are inferred from the claim text.